Barclays
APYX icon

Barclays’s Apyx Medical APYX Stock Holding History

Barclays’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58K Sell
352
-87
-20% -$345 ﹤0.01% 4894
2026
Q1 		$1.62K Buy
+439
New +$1.64K ﹤0.01% 4869
2023
Q4 		– Sell
-14,284
Closed -$45.7K – 5219
2023
Q3 		$45.7K Buy
+14,284
New +$66.6K ﹤0.01% 3912
2023
Q1 		– Sell
-842,145
Closed -$1.97M – 5076
2022
Q4 		$1.97M Buy
+842,145
New +$2.57M ﹤0.01% 2279
2021
Q3 		– Sell
-546
Closed -$6K – 4735
2021
Q2 		$6K Buy
+546
New +$5.41K ﹤0.01% 4726
2021
Q1 		– Sell
-10,792
Closed -$78K – 4676
2020
Q4 		$78K Sell
10,792
-4,634
-30% -$30.7K ﹤0.01% 4232
2020
Q3 		$73K Sell
15,426
-3,079
-17% -$15.2K ﹤0.01% 4408
2020
Q2 		$102K Buy
+18,505
New +$76.9K ﹤0.01% 4503
2020
Q1 		– Sell
-9
Closed – – 6116
2019
Q4 		$0 Sell
9
-16,816
-100% -$121K ﹤0.01% 6321
2019
Q3 		$114K Sell
16,825
-9,100
-35% -$64.6K ﹤0.01% 5376
2019
Q2 		$174K Buy
25,925
+25,762
+15,805% +$140K ﹤0.01% 5241
2019
Q1 		$1K Sell
163
-123,254
-100% -$954K ﹤0.01% 6894
2018
Q4 		$800K Buy
+123,417
New +$748K ﹤0.01% 3340
2018
Q3 		– Sell
-44
Closed – – 7091
2018
Q2 		$0 Sell
44
-520
-92% -$1.92K ﹤0.01% 6943
2018
Q1 		$2K Buy
564
+506
+872% +$1.3K ﹤0.01% 6889
2017
Q4 		$0 Sell
58
-6
-9% -$19 ﹤0.01% 6906
2017
Q3 		$0 Sell
64
-214
-77% -$552 ﹤0.01% 6826
2017
Q2 		$1K Buy
278
+184
+196% +$452 ﹤0.01% 6485
2017
Q1 		$0 Buy
+94
New +$312 ﹤0.01% 6736

Other funds holding APYX

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's APYX Position: Q2 2026 in Review

Barclays reduced its Apyx Medical (APYX) stake by 20% in Q2 2026, selling an estimated $345 and leaving 352 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #4894.

Barclays first reported a position in APYX in Q1 2017 and has held it in 19 quarters since. The position peaked at $1.97M in Q4 2022. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

  • Barclays held 352 shares of Apyx Medical worth $1.58K as of Q2 2026.
  • Barclays sold 87 Apyx Medical shares in Q2 2026, an estimated $345.
  • Apyx Medical made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4894 holding.
  • Barclays first reported a position in Apyx Medical in Q1 2017 and has held it in 19 quarters since.
  • Barclays's Apyx Medical position peaked at $1.97M in Q4 2022.
  • 68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.